Evidence mapPaperPMID 23299643Full record

ReviewCurrent atherosclerosis reports2013

Pharmacologic interactions of multidrug therapy for dyslipidemia.

Nidhi Mehta, Emil M deGoma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Nidhi MehtaDivision of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, 9 Gates Building 3400 Spruce Street, Philadelphia, PA 19103, USA. nidhi.mehta@uphs.upenn.edu
Emil M deGoma
United Heart and Vascular Clinic · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the best available medical therapy inclusive of statins, substantial residual risk remains for atherothrombotic cardiovascular disease. Non-statin lipid-lowering therapy may help address this critical unmet need through reduction of the levels of low-density lipoprotein and other atherogenic lipoproteins. In the past few years, several landmark trials have provided important information regarding the efficacy and safety of non-statin therapy for dyslipidemia and cardiovascular risk reduction.

Indexed as

DyslipidemiasDrug InteractionsDrug TherapyGlobal HealthHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsIncidenceLipidsTreatment OutcomeHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLipids

Identifiers

PMID23299643
OpenAlexW1968092423

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.